Sophia Genetics, the European leader in Data-Driven Medicine, has raised $13.75M in Series B financing in a round led by Dr Mike Lynch’s Invoke Capital, Endeavour Vision and Swisscom. The investment aims to accelerate European adoption of clinical analytics for genetic diseases.
Sophia Genetics is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases. With this investment, Sophia gains access to Invoke’s portfolio company Genalys, whose Cambridge-based mathematicians apply big data approaches to genomic information. The combination means that clinicians and hospitals across Europe gain access to very accurate clinical analytics service for early diagnosis and optimized treatment of cancer and genetic diseases.